학술논문
The combination of ipilimumab and nivolumab is still not reimbursed for BRAF-mutated melanoma patients in France: An unacceptable medical situation that raises ethical concerns
Document Type
Correspondence
Author
Amini-Adle, M.; Arnault, J.-P.; Aubin, F.; Beneton, N.; Bens, G.; Brunet-Possenti, F.; Célerier, P.; Charles, J.; Crumbach, L.; Dalac, S.; Darras, S.; De Quatrebarbes, J.; Dinulescu, M.; Dutriaux, C.; Gaudy, C.; Gérard, E.; Giacchero, D.; Granel-Brocard, F.; Grange, F.; Jouary, T.; Kramkimel, N.; Lebbé, C.; Le Corre, Y.; Legoupil, D.; Lesage, C.; Lesimple, T.; Lorphelin, J.-M.; Mansard, S.; Martin, L.; Mary-Prey, S.; Maubec, E.; Meyer, N.; Mignard, C.; Montaudie, H.; Mortier, L.; Nardin, C.; Neidhardt Berard, E.-M.; Pagès Laurent, C.; Peuvrel, L.; Quereux, Gaelle; Robert, Caroline; Saiag, Philippe; Saint-Jean, Mélanie; Samimi, M.; Sassolas, B.; Scalbert, C.; Skowron, F.; Steff, M.; Stoebner, P.-E.; Trablesi, S.; Visseaux, L.; Zehou, O.; Boespflug, A.
Source
In Annales de Dermatologie et de Vénéréologie March 2024 151(1)
Subject
Language
ISSN
0151-9638